CBER Director Peter Marks (Susan Walsh/Pool via AP Images)
June 21, 2024 04:00 PM EDTUpdated June 24, 03:40 PM
Pharma
Cell/Gene Tx
FDA+

Pe­ter Marks sin­gle-hand­ed­ly ap­proved Sarep­ta’s gene ther­a­py — what does that mean for every­one else?

Lei Lei Wu

News Reporter

Is Sarep­ta spe­cial? Or has the FDA set a new prece­dent for how it ap­proach­es treat­ments for dev­as­tat­ing dis­eases with few op­tions?

On Thurs­day, the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

A service from the Financial Times